Abstracts
Background
Patients with T2N0 squamous cell carcinoma of the anal canal (SCCA) have comprised
less than 30% of patients enrolled in phase III clinical trials of curative-intent
definitive chemoradiation. We aimed to evaluate treatment outcomes of these patients
according to dose-intensity of chemoradiation.
Materials and Methods
Retrospective multicenter study of patients with T2N0 SCCA, with the primary endpoint
to compare the progression-free survival (PFS) of patients treated with full definitive
chemoradiotherapy (f-CRT, CRT with 2 drugs) versus a nonstandard treatment (NST; radiotherapy
only or CRT with 1 drug). Secondary outcomes were rates of complete response (CR),
salvage surgery, and colostomy. PFS time was analyzed using the Kaplan-Meier method
and differences in survival outcomes were assessed using the log-rank test and adjusted
for prognostic covariates using a multivariable Cox regression model
Results
From March 2006 to January 2020, 74 patients were included. Most patients (n = 58; 78.4%) received f-CRT. In a median follow up time of 66.1 months, the unadjusted
median PFS was 128.3 months (95% confidence interval [CI] 105.5-151.1) for f-CRT versus
74.1 months for NST (95% CI 45.8-102.4; P = .067). CR was achieved by 51 (87.9%) versus 11 (68.9%; P = .065) patients treated with f-CRT or an NST, respectively. Comparing f-CRT versus
NST, the colostomy rates were higher for those treated with an NST: 5 (32.8%) versus
5 (9.5%; P = .019)
Conclusion
For patients with T2N0 SCCA, f-CRT remains the standard treatment, offering higher
CR and less likelihood of colostomy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2020.CA Cancer J Clin. 2020; https://doi.org/10.3322/caac.21590
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2021; https://doi.org/10.3322/caac.21660
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial.Lancet Oncol. 2013; 14: 516-524https://doi.org/10.1016/S1470-2045(13)70086-X
- Disease-free survival and time to complete response after definitive chemoradiotherapy for squamous-cell carcinoma of the anus according to HIV infection.Clin Colorectal Cancer. 2020; https://doi.org/10.1016/j.clcc.2020.03.006
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin.Lancet. 1996; https://doi.org/10.1016/S0140-6736(96)03409-5
- Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.Dis Colon Rectum. 2013; https://doi.org/10.1097/DCR.0b013e3182a226bd
- Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort.Radiother Oncol. 2013; https://doi.org/10.1016/j.radonc.2013.05.037
- Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal.Int J Radiat Oncol Biol Phys. 2003; https://doi.org/10.1016/S0360-3016(03)00417-6
- Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?.Radiother Oncol. 2012; https://doi.org/10.1016/j.radonc.2011.09.015
- Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study.J Clin Oncol. 1996; https://doi.org/10.1200/JCO.1996.14.9.2527
- Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastro.J Clin Oncol. 1997; https://doi.org/10.1200/JCO.1997.15.5.2040
- Combined radiotherapy and chemotherapy for anal cancer.Lancet. 1997; https://doi.org/10.1016/s0140-6736(05)60945-2
- Stage I squamous cell carcinoma of the anus: Is radiation therapy alone sufficient treatment?.Cancers (Basel). 2020; https://doi.org/10.3390/cancers12113248
- 402P Chemoradiation versus less intensive treatments in stage I squamous cell carcinoma of the anal canal (SCCA).Ann Oncol. 2021; https://doi.org/10.1016/j.annonc.2021.08.924
- De-escalation of therapy for patients with early-stage squamous cell carcinoma of the anus.Cancers (Basel). 2021; https://doi.org/10.3390/cancers13092099
- Prospective study of biomarkers in squamous cell carcinoma of the anal canal (SCCAC) and their influence on treatment outcomes: Final results.J Clin Oncol. 2017; https://doi.org/10.1200/jco.2017.35.15_suppl.3577
- Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis.J Gastrointest Oncol. 2018; 10: 48-60https://doi.org/10.21037/jgo.2018.10.08
- Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.J Clin Oncol. 2014; https://doi.org/10.1200/JCO.2013.52.3464
Article info
Publication history
Published online: June 06, 2022
Accepted:
March 11,
2022
Received in revised form:
March 8,
2022
Received:
January 5,
2022
Identification
Copyright
© 2022 Published by Elsevier Inc.
